← Back to patent-cliff list
GL-101
Tier C — Watch / tradeGL-101
Gliacure Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：Updating
Indications (approved)：Graft-versus-host disease, Ophthalmic disease, Dry eye syndrome, Keratoconjunctivitis sicca
Regional status
US
Phase III
2021-04-15
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of GL-101?
Approved indications include: Graft-versus-host disease, Ophthalmic disease, Dry eye syndrome, Keratoconjunctivitis sicca.
When does the GL-101 patent expire?
No public expiry year is available for GL-101 yet; this page updates once verified.
How do I get a quote for GL-101 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21